Projects per year
Equipments Details
Description
Our Fragment Based Drug Design platform (MFP) provides academic and commercial researchers with access to fragment-based drug discovery technologies for their therapeutic targets. The facilities are located at the Monash Institute of Pharmaceutical Sciences – Australia’s largest and most successful pharmaceutical institute. FBDD screening uses our high-quality, in-house fragment library designed to maximise chemical space coverage and enable rapid hit optimisation. Screening cascades are
tailored for each target and can be performed using a variety of techniques including NMR spectroscopy and our surface plasmon resonance (SPR) facility.
tailored for each target and can be performed using a variety of techniques including NMR spectroscopy and our surface plasmon resonance (SPR) facility.
-
Developing new tools for chemical biology
Scanlon, M., Porter, C., Halls, M. & Doak, B.
1/01/20 → 31/12/22
Project: Research
-
Immunobiology and Immunotherapy of Cancer
Trapani, J. & Whisstock, J.
1/01/18 → 31/12/22
Project: Research
-
Synthesis of 19F-13C labelled aromatic amino acid probes for the investigation of protein structure and dynamics by 19F-TROSY-NMR spectroscopy.
Kopinathan, A.
1/10/20 → 31/12/21
Project: Research